CALCB Recombinant Antibody for Enhanced Research & Diagnostic Applications

CALCB recombinant antibody is a cutting-edge product developed by Alpha Lifetech Incorporation, designed to facilitate advanced research in the field of molecular biology. This high-quality recombinant antibody specifically targets Calcitonin Gene-Related Peptide (CALCB), a crucial Protein involved in various physiological processes, including pain modulation and inflammation regulation, Characterized by high specificity and affinity, CALCB recombinant antibody enhances the accuracy of experimental results, making it an essential tool for researchers in immunology, neurology, and related disciplines. Alpha Lifetech Incorporation ensures rigorous quality control measures during production, providing a consistent and reliable product that meets the demands of modern scientific research, Whether you are conducting basic research, drug development, or exploring novel therapeutic strategies, CALCB recombinant antibody will empower scientists to uncover new insights into CALCB’s role in health and disease. Elevate your research potential with this exceptional antibody, tailored for excellence and innovation in scientific discovery

Hot Selling Product

ADT1255-Fremanezumab Biosimilar-Anti-CALCA , CALCB mAb-Research Grade

ADT1332-J695 Biosimilar-Recombinant Human Monoclonal Antibody

ALP64508-Recombinant Human Siglec-10 Protein, Fc Tag

ALP64509-Recombinant Human Siglec-10 Protein, mFc Tag

ALP64511-Recombinant Cynomolgus Monkey TNFRSF17/BCMA Protein, His Tag

ALP64514-Recombinant Human 5T4/TPBG Protein, Avi Tag, His Tag

Today's Choice of CALCB recombinant antibody Industry Giant Factory

In the rapidly evolving field of biotechnology, Alpha Lifetech Inc. stands tall as a beacon of innovation, particularly in the realm of CALCB recombinant antibodies. Founded by a team of seasoned scientists, Alpha Lifetech has specialized expertise in membrane protein production, Nanobody discovery, and monoclonal development. With nearly 10,000 high-quality reagents, including spot membrane protein reagents, cytokines, and drug target antibodies, we are committed to providing top-tier solutions that meet the diverse needs of global procurement teams. Today's choice of CALCB recombinant antibodies from our industry-leading factory reflects our dedication to quality and precision. Each antibody is meticulously developed through sophisticated methodologies, ensuring optimal performance and reliability in various research applications. Our cutting-edge production techniques and rigorous quality control measures guarantee that our products not only meet but exceed the standards expected in the biotechnology sector. Partnering with Alpha Lifetech means gaining access to unparalleled expertise and a comprehensive range of high-quality reagents. With our scientists' commitment to advancing research and therapeutic applications, we are ready to support your procurement needs and help drive your projects forward. Explore the possibilities with Alpha Lifetech and experience the difference of working with an industry giant at the forefront of biotechnological advancements.

Today's Choice of CALCB Recombinant Antibody Industry Giant Factory

Antibody Type	Source	Host Species	Applications	Price (USD)
anti-CALCB IgG	Recombinant	Rabbit	WB, IHC	150
Anti-CALCB Mouse IgG	Recombinant	Mouse	ELISA	120
Anti-CALCB Goat IgG	Recombinant	Goat	Immunoprecipitation	180

Annual Growth Trend of CALCB Recombinant Antibody Production (2018-2023)

The production volume of CALCB recombinant antibodies has shown significant growth from 2018 to 2023. In 2018, the production was 200 kg, and it steadily increased over the years. By 2019, production rose to 350 kg, demonstrating a robust growth trend. The upward trajectory continued with an increase to 400 kg in 2020, further escalating to 600 kg in 2021. The growth rate accelerated, with production reaching 800 kg in 2022. As of 2023, the total production volume has achieved an impressive 1100 kg. This steady increase indicates a rising demand and improved manufacturing capabilities in the industry, signaling a positive outlook for CALCB recombinant antibodies in the future.